Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > Feline patent action for BOEHRINGER INGELHEIM ANIMAL HEALTH
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1064)
•••
Post by Pandoraon Sep 15, 2022 7:01pm
333 Views
Post# 34965699

Feline patent action for BOEHRINGER INGELHEIM ANIMAL HEALTH

Feline patent action for BOEHRINGER INGELHEIM ANIMAL HEALTH Non-final rejection normally means the examiner did not like some things and now the Company has 90 days to respond.

USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREAT-MENT OF CARDIAC DISEASES IN FELINES

09/15/2022 CTNF Non-Final Rejection 19 Preview DOCX / PDF / XML
09/15/2022 892 List of references cited by examiner 1 Preview PDF
09/15/2022 SRFW Search information including classification, databases and other search related notes 1 Preview PDF
09/15/2022 1449 List of References cited by applicant and considered by examiner 5 Preview PDF
09/15/2022 SRNT Examiner's search strategy and results 2 Preview PDF
09/15/2022 SRNT Examiner's search strategy and results 2 Preview PDF
09/15/2022 NPL Non Patent Literature 19 Preview    
09/15/2022 SRNT Examiner's search strategy and results 2 Preview PDF
09/15/2022 SRNT Examiner's search strategy and results

28515 - C/O AH PATENT DEPARTMENT
BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
3239 SATELLITE BLVD.
BLDG. 500
DULUTH, GA
UNITED STATES
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities